These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 29127931)

  • 21. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2013 Nov; 67(11):1089-104. PubMed ID: 24016209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.
    Asnis GM; Bose A; Gommoll CP; Chen C; Greenberg WM
    J Clin Psychiatry; 2013 Mar; 74(3):242-8. PubMed ID: 23561229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G; Gislum M; Filippov G; Montgomery S
    Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment.
    Christensen MC; McIntyre RS; Florea I; Loft H; Fagiolini A
    CNS Spectr; 2023 Feb; 28(1):90-97. PubMed ID: 34657638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.
    Bruno A; Morabito P; Spina E; Muscatello MR
    Curr Neuropharmacol; 2016; 14(2):191-9. PubMed ID: 26572745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.
    Bakish D; Bose A; Gommoll C; Chen C; Nunez R; Greenberg WM; Liebowitz M; Khan A
    J Psychiatry Neurosci; 2014 Jan; 39(1):40-9. PubMed ID: 24144196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials.
    Jain R; Chen D; Edwards J; Mathews M
    Curr Med Res Opin; 2014 Feb; 30(2):263-70. PubMed ID: 24127687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
    Nomikos GG; Tomori D; Zhong W; Affinito J; Palo W
    CNS Spectr; 2017 Aug; 22(4):348-362. PubMed ID: 27869048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Mathews M; Gommoll C; Chen D; Nunez R; Khan A
    Int Clin Psychopharmacol; 2015 Mar; 30(2):67-74. PubMed ID: 25500685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults.
    Thase ME; Mahableshwarkar AR; Dragheim M; Loft H; Vieta E
    Eur Neuropsychopharmacol; 2016 Jun; 26(6):979-93. PubMed ID: 27139079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.
    Saraceni MM; Venci JV; Gandhi MA
    J Pharm Pract; 2014 Aug; 27(4):389-95. PubMed ID: 24381243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
    Baldwin DS; Florea I; Jacobsen PL; Zhong W; Nomikos GG
    J Affect Disord; 2016 Dec; 206():140-150. PubMed ID: 27474960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
    Baldwin DS; Chrones L; Florea I; Nielsen R; Nomikos GG; Palo W; Reines E
    J Psychopharmacol; 2016 Mar; 30(3):242-52. PubMed ID: 26864543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis.
    Jacobsen PL; Mahableshwarkar AR; Palo WA; Chen Y; Dragheim M; Clayton AH
    CNS Spectr; 2016 Oct; 21(5):367-378. PubMed ID: 26575433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials.
    Shi L; Wang J; Xu S; Lu Y
    Drug Des Devel Ther; 2016; 10():3899-3907. PubMed ID: 27932864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vortioxetine: a New Treatment for Major Depressive Disorder.
    Connolly KR; Thase ME
    Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
    Khan A; Cutler AJ; Kajdasz DK; Gallipoli S; Athanasiou M; Robinson DS; Whalen H; Reed CR
    J Clin Psychiatry; 2011 Apr; 72(4):441-7. PubMed ID: 21527122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.